Douglas Sadrac de Biagi Ferreira

Douglas Sadrac de Biagi Ferreira

Auto-generated profile, based on publicly available information

Douglas Sadrac de Biagi Ferreira

Universidade Estadual Paulista (Unesp) image/svg+xml

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Revista de Odontologia da UNESP
Verified
Journal Article
Open access
JOJúlio César Silva de Oliveira
Júlio César Silva de Oliveira
IDIzabela Fornazari Delamura
Izabela Fornazari Delamura
DFDouglas Sadrac de Biagi Ferreira
Douglas Sadrac de Biagi Ferreira
AVArthur Henrique Alécio Viotto
Arthur Henrique Alécio Viotto
GPGuilherme Alexandre Silva Prado
Guilherme Alexandre Silva Prado
ABAna Paula Bassi
Ana Paula Bassi
Introduction Mandibular third molar surgery may cause postoperative pain and neurosensory disturbances. The choice of local anesthetic may influence these outcomes. Objective To compare postoperative pain intensity and the occurrence of paresthesia following mandibular third molar surgery using 4% articaine or 2% mepivacaine as local anesthetics. Material and method A randomized, double-blind, split-mouth clinical trial was conducted with 30 healthy patients undergoing bilateral mandibular third molar extractions. All procedures were performed by a single surgeon. According to a randomized sequence, each patient received 2% mepivacaine on one side and 4% articaine on the contralateral side. Postoperative pain intensity was assessed at 6, 12, and 24 hours using a validated pain scale. Paresthesia was evaluated through patient questionnaires and neurosensory testing at 7 and 30 days after surgery. Result No cases of persistent paresthesia were observed in either group. Pain intensity did not differ significantly between anesthetic solutions at 6 or 12 hours postoperatively. However, at 24 hours, patients receiving mepivacaine reported significantly higher pain scores than those receiving articaine (p < 0.05). Both anesthetics provided adequate intraoperative anesthesia. Conclusion Both anesthetic solutions were safe and effective for mandibular third molar surgery. However, 4% articaine provided superior postoperative analgesia at 24 hours without increasing the risk of persistent paresthesia.

2 September 2026 in SciELO Preprints
Verified
Preprint
Open access
JOJúlio César Silva de Oliveira
Júlio César Silva de Oliveira
IDIzabela Fornazari Delamura
Izabela Fornazari Delamura
DFDouglas Sadrac de Biagi Ferreira
Douglas Sadrac de Biagi Ferreira
AVArthur Henrique Alécio Viotto
Arthur Henrique Alécio Viotto
GPGuilherme Alexandre Silva Prado
Guilherme Alexandre Silva Prado
ABAna Paula Bassi
Ana Paula Bassi
Objective: To compare postoperative pain intensity and the occurrence of paresthesia following mandibular third molar surgery using 4% articaine or 2% mepivacaine as local anesthetics. Material and method: A randomized, double-blind, split-mouth clinical trial was conducted with 30 healthy patients undergoing bilateral mandibular third molar extractions. All procedures were performed by a single surgeon. According to a randomized sequence, each patient received 2% mepivacaine on one side and 4% articaine on the contralateral side. Postoperative pain intensity was assessed at 6, 12, and 24 hours using a validated pain scale. Paresthesia was evaluated through patient questionnaires and neurosensory testing at 7 and 30 days after surgery. Result: No cases of persistent paresthesia were observed in either group. Pain intensity did not differ significantly between anesthetic solutions at 6 or 12 hours postoperatively. However, at 24 hours, patients receiving mepivacaine reported significantly higher pain scores than those receiving articaine (p < 0.05). Both anesthetics provided adequate intraoperative anesthesia. Conclusion: Both anesthetic solutions were safe and effective for mandibular third molar surgery. However, 4% articaine provided superior postoperative analgesia at 24 hours without increasing the risk of persistent paresthesia.